David E. Mery

Postdoctoral Fellow

UAMS

Also affiliated: University of Arkansas Medical Center (2023); Weill Cornell Medicine (2019)

8 h-index 34 pubs 206 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

David E. Mery's research focuses on multiple myeloma and its precursor stages, investigating alterations in the immune microenvironment and identifying potential therapeutic targets. He has contributed to studies on bispecific CAR-T cell therapy for multiple myeloma growth control and the role of NEK2 expression in suppressing T cell immunity within the disease context. Mery's work also includes the development and validation of prognostic scoring systems for patients with newly diagnosed multiple myeloma, such as the Myeloma Prognostic Score System (MPSS).

His research has explored predictive markers for disease progression, including gene signatures that can indicate the risk of monoclonal gammopathy of undetermined significance (MGUS) progressing to multiple myeloma. Mery has also examined the application of risk stratification tools like the R2-ISS score in patients undergoing autologous stem cell transplantation. His earlier work includes investigations into the anti-leukemic activity of specific compounds, such as cranberry A-type proanthocyanidins and dehydroleucodine adducts.

Metrics

h-index: 8
Publications: 34
Citations: 206

Positions

Postdoctoral Fellow 2021–present

University of Arkansas for Medical Sciences Internal Medicine ORCID

Selected Publications

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma (2026)

Blood DOI OpenAlex
Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum (2025)

Blood DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

Cancer Biomarkers 1 citation DOI OpenAlex
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma (2025)

Blood 6 citations DOI OpenAlex
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets (2025)

Cell Reports Medicine 4 citations DOI OpenAlex
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)

Blood DOI OpenAlex
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)

Blood DOI OpenAlex
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)

Blood 1 citation DOI OpenAlex
The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment (2024)

Blood DOI OpenAlex
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)

Blood Cancer Journal 38 citations DOI OpenAlex
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)

Cancers 4 citations DOI OpenAlex
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)

Blood Cancer Journal 7 citations DOI OpenAlex
Development and validation of an individualized and weighted Myeloma Prognostic Score System ( MPSS ) in patients with newly diagnosed multiple myeloma (2024)

American Journal of Hematology 19 citations DOI OpenAlex
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)

Nature Communications 47 citations DOI OpenAlex
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions (2023)

Journal of Clinical Investigation 7 citations DOI OpenAlex